WallStreetZenWallStreetZen

NASDAQ: NKTR
Nektar Therapeutics Stock Forecast, Predictions & Price Target

Analyst price target for NKTR

Based on 2 analysts offering 12 month price targets for Nektar Therapeutics.
Min Forecast
$4.00+187.77%
Avg Forecast
$5.50+295.68%
Max Forecast
$7.00+403.6%

Should I buy or sell NKTR stock?

Based on 2 analysts offering ratings for Nektar Therapeutics.
Strong Buy
Strong Buy
2 analysts 100%
Buy
0 analysts 0%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their NKTR stock forecasts and price targets.

NKTR stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-11-04
lockedlocked$00.00+00.00%2024-09-30

1 of 1

Forecast return on equity

Is NKTR forecast to generate an efficient return?
Company
-166.32%
Industry
146.17%
Market
72.3%
NKTR's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is NKTR forecast to generate an efficient return on assets?
Company
-38.6%
Industry
22.86%
NKTR is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

NKTR earnings per share forecast

What is NKTR's earnings per share in the next 3 years based on estimates from 6 analysts?
Avg 1 year Forecast
-$0.85
Avg 2 year Forecast
-$0.70
Avg 3 year Forecast
-$0.72

NKTR revenue forecast

What is NKTR's revenue in the next 3 years based on estimates from 6 analysts?
Avg 1 year Forecast
$77.8M-16.44%
Avg 2 year Forecast
$65.3M-29.95%
Avg 3 year Forecast
$67.9M-27.16%
NKTR's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

NKTR revenue growth forecast

How is NKTR forecast to perform vs Biotechnology companies and vs the US market?
Company
-11.16%
Industry
37.67%
Market
9.3%
NKTR's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
NKTR's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

NKTR vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
NKTR$1.39$5.50+295.68%Strong Buy
TSVT$4.95$7.33+48.14%Buy
ACRV$8.37$20.75+147.91%Strong Buy
CMPX$1.83$7.67+318.96%Strong Buy
XBIT$8.25N/AN/A

Nektar Therapeutics Stock Forecast FAQ

Is Nektar Therapeutics Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 2 Wall Street analysts covering (NASDAQ: NKTR) stock is to Strong Buy NKTR stock.

Out of 2 analysts, 2 (100%) are recommending NKTR as a Strong Buy, 0 (0%) are recommending NKTR as a Buy, 0 (0%) are recommending NKTR as a Hold, 0 (0%) are recommending NKTR as a Sell, and 0 (0%) are recommending NKTR as a Strong Sell.

If you're new to stock investing, here's how to buy Nektar Therapeutics stock.

What is NKTR's earnings growth forecast for 2024-2026?

(NASDAQ: NKTR) Nektar Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 13.36%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 17.69%.

Nektar Therapeutics's earnings in 2024 is -$177,081,000.On average, 6 Wall Street analysts forecast NKTR's earnings for 2024 to be -$155,860,095, with the lowest NKTR earnings forecast at -$178,557,095, and the highest NKTR earnings forecast at -$139,900,404. On average, 6 Wall Street analysts forecast NKTR's earnings for 2025 to be -$128,855,635, with the lowest NKTR earnings forecast at -$185,920,274, and the highest NKTR earnings forecast at -$58,905,433.

In 2026, NKTR is forecast to generate -$132,537,225 in earnings, with the lowest earnings forecast at -$193,283,453 and the highest earnings forecast at -$36,815,896.

What is NKTR's revenue growth forecast for 2024-2026?

(NASDAQ: NKTR) Nektar Therapeutics's forecast annual revenue growth rate of -11.16% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.67%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.3%.

Nektar Therapeutics's revenue in 2024 is $93,157,000.On average, 6 Wall Street analysts forecast NKTR's revenue for 2024 to be $14,329,298,884, with the lowest NKTR revenue forecast at $10,032,331,606, and the highest NKTR revenue forecast at $15,736,954,660. On average, 6 Wall Street analysts forecast NKTR's revenue for 2025 to be $12,012,106,402, with the lowest NKTR revenue forecast at $4,215,420,069, and the highest NKTR revenue forecast at $16,143,770,308.

In 2026, NKTR is forecast to generate $12,490,713,048 in revenue, with the lowest revenue forecast at $4,344,275,704 and the highest revenue forecast at $17,986,405,893.

What is NKTR's forecast return on assets (ROA) for 2024-2027?

(NASDAQ: NKTR) forecast ROA is -38.6%, which is lower than the forecast US Biotechnology industry average of 22.86%.

What is NKTR's Price Target?

According to 2 Wall Street analysts that have issued a 1 year NKTR price target, the average NKTR price target is $5.50, with the highest NKTR stock price forecast at $7.00 and the lowest NKTR stock price forecast at $4.00.

On average, Wall Street analysts predict that Nektar Therapeutics's share price could reach $5.50 by Nov 4, 2025. The average Nektar Therapeutics stock price prediction forecasts a potential upside of 295.68% from the current NKTR share price of $1.39.

What is NKTR's Earnings Per Share (EPS) forecast for 2024-2026?

(NASDAQ: NKTR) Nektar Therapeutics's current Earnings Per Share (EPS) is -$0.90. On average, analysts forecast that NKTR's EPS will be -$0.85 for 2024, with the lowest EPS forecast at -$0.97, and the highest EPS forecast at -$0.76. On average, analysts forecast that NKTR's EPS will be -$0.70 for 2025, with the lowest EPS forecast at -$1.01, and the highest EPS forecast at -$0.32. In 2026, NKTR's EPS is forecast to hit -$0.72 (min: -$1.05, max: -$0.20).

What is NKTR's forecast return on equity (ROE) for 2024-2027?

(NASDAQ: NKTR) forecast ROE is -166.32%, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.